AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04840134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk
Description: The intervention will be delivered in two consecutive phases:~1. Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~2. Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~1. Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~2. One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~3. Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief).
Study NCT04913740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ointment and dressing for external use
Description: 1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor
Study NCT06507683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
Description: A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD
Study NCT06287307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Study NCT06520930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise therapy
Description: Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
Study NCT04627428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPESC-RPE-4W
Description: RPESC-RPE-4W
Study NCT05022212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LACTIN-V
Description: administered vaginally
Study NCT05022212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered vaginally
Study NCT06226181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy and amniotic membrane
Description: Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
Study NCT06226181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dacryocystorhinostomy
Description: Conventional dacryocystorhinostomy surgery without adding amniotic membrane
Study NCT06116630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DCE-MRI
Description: Both groups will undergo DCE-MRIs.
Study NCT04881487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Additional stereotactic body radiation therapy
Description: 5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
Study NCT06287307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Description: The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Study NCT05435118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMONO + audiovisuals tool
Description: EMONO + use of audiovisuals tool on smartphone or tablet
Study NCT04748133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture needles
Description: Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist
Study NCT05374070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)
Description: Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT05374070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included
Description: In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT05374070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)
Description: In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT05374070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included
Description: In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study NCT04860674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor +ICE
Description: PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
Study NCT04748133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no treatment
Study NCT04797962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: dedicated case management to address social support needs
Study NCT04841369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular
Study NCT04817618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study NCT04817618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iptacopan
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study NCT04841369 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular
Study NCT04841369 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL,Intramuscular
Study NCT03209063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polymerase chain reaction
Description: diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
Study NCT06039423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The M-TAPA block
Description: A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
Study NCT06039423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: conventional general anaesthesia receiving multimodal analgesia
Study NCT05162599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic study, experimental evaluative cross-sectional study
Description: This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
Study NCT05670561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Study NCT05517694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises and behavioral therapy
Description: Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
Study NCT05517694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises and behavioral therapy
Description: Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
Study NCT05517694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercises
Description: Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks.
Study NCT05450627 — intervention group
Intervention type: DRUG
Intervention: Pancreatic Enzyme
Description: Registry of pancreatic enzyme therapy prescribed to included patients
Study NCT05345028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lecithin-based delivery form of Boswellia serrata
Description: 250 mg for 5 days
Study NCT05345028 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mg for 5 days
Study NCT04683120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zenith FLIM Diagnostics
Description: In-vitro
Study NCT06102109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: 25gauge pars plana vitrectomy: to remove the vitreous if present
Study NCT06102109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL explantation
Description: Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
Study NCT06102109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral IOL fixation Yamane Technique
Description: Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
Study NCT06102109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral IOL fixation 4-flanged Technique
Description: Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
Study NCT04805710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel combined with rivaroxaban arm
Description: Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
Study NCT06100874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
Study NCT06100874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
Study NCT06100874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Hyaluronidase-oysk
Description: Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
Study NCT05994833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPT
Description: The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
Study NCT05154838 — intervention group
Intervention type: PROCEDURE
Intervention: Drainage and packing of pilonidal abscess
Description: Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
Study NCT05625074 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional surgery for great saphenous vein insufficiency
Description: Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
Study NCT06578273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroGlove
Description: The NeuroGlove is a plastic chamber with multiple apertures along its length to allow for puffs of air to be directed to the volar surface of the distal forearm, the palm, and the fingers. The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development. A pneumatic pump delivers intermittent puffs of air cycling between one second on and two seconds off. The hand with the palm facing up is placed within the device chamber on a gel pad to provide a comfortable resting surface for the duration of the treatment, which lasts approximately thirty minutes.~The device facilitates the rehabilitation, improvement, or restoration of motion in patients with neurological disorders.
Study NCT05089669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive e-book
Description: The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
Study NCT05089669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper textbook
Description: The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
Study NCT05146843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone
Description: Mitoquinone pill, 20 mg/day
Study NCT05146843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, 20 mg/day
Study NCT05456958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Biofeedback
Description: We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
Study NCT05456958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham-MRI Biofeedback
Description: In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
Study NCT05899296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental syringe ( NumBee)
Description: assess the capability of NumBee to reduce anxiety and pain during injection
Study NCT05899296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional dental syringe
Description: compare the level of anxiety of the traditional dental syringe and the Number dental syringe
Study NCT05064449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets.
Study NCT05064449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution.
Study NCT05064449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Description: Mefenamic acid capsule.
Study NCT04806191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence based treatment strategy
Description: Evidence-based clinical examination and treatment plan
Study NCT04806191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted patient information package
Description: GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).